nodes	percent_of_prediction	percent_of_DWPC	metapath
Terlipressin—Torsade de pointes—Vandetanib—thyroid cancer	0.0284	0.0599	CcSEcCtD
Terlipressin—AVPR2—Vasopressin regulates renal water homeostasis via Aquaporins—PRKAR1A—thyroid cancer	0.0268	0.051	CbGpPWpGaD
Terlipressin—AVPR1B—Peptide GPCRs—TSHR—thyroid cancer	0.0257	0.0488	CbGpPWpGaD
Terlipressin—AVPR2—Arf6 trafficking events—TSHR—thyroid cancer	0.0254	0.0483	CbGpPWpGaD
Terlipressin—AVPR2—G alpha (s) signalling events—CALCB—thyroid cancer	0.0252	0.048	CbGpPWpGaD
Terlipressin—AVPR2—Aquaporin-mediated transport—PRKAR1A—thyroid cancer	0.0234	0.0445	CbGpPWpGaD
Terlipressin—Respiratory distress—Sorafenib—thyroid cancer	0.0212	0.0446	CcSEcCtD
Terlipressin—Respiratory failure—Vandetanib—thyroid cancer	0.0203	0.0428	CcSEcCtD
Terlipressin—AVPR1A—Peptide GPCRs—TSHR—thyroid cancer	0.0178	0.0338	CbGpPWpGaD
Terlipressin—AVPR2—Peptide GPCRs—TSHR—thyroid cancer	0.0177	0.0336	CbGpPWpGaD
Terlipressin—Atrial fibrillation—Vandetanib—thyroid cancer	0.0153	0.0322	CcSEcCtD
Terlipressin—Cardiac failure—Vandetanib—thyroid cancer	0.0148	0.0313	CcSEcCtD
Terlipressin—Hyponatraemia—Vandetanib—thyroid cancer	0.0145	0.0306	CcSEcCtD
Terlipressin—Skin necrosis—Epirubicin—thyroid cancer	0.0142	0.03	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—CALCB—thyroid cancer	0.0133	0.0253	CbGpPWpGaD
Terlipressin—Skin necrosis—Doxorubicin—thyroid cancer	0.0132	0.0278	CcSEcCtD
Terlipressin—Skin exfoliation—Sorafenib—thyroid cancer	0.0128	0.0271	CcSEcCtD
Terlipressin—AVPR2—G alpha (s) signalling events—TSHR—thyroid cancer	0.0117	0.0222	CbGpPWpGaD
Terlipressin—Bradycardia—Vandetanib—thyroid cancer	0.0102	0.0215	CcSEcCtD
Terlipressin—Cardiac failure—Sorafenib—thyroid cancer	0.01	0.0211	CcSEcCtD
Terlipressin—Hyponatraemia—Sorafenib—thyroid cancer	0.0098	0.0207	CcSEcCtD
Terlipressin—AVPR1B—Peptide ligand-binding receptors—SST—thyroid cancer	0.00938	0.0179	CbGpPWpGaD
Terlipressin—Cardiac disorder—Vandetanib—thyroid cancer	0.00929	0.0196	CcSEcCtD
Terlipressin—AVPR1A—GPCR ligand binding—CALCB—thyroid cancer	0.00923	0.0176	CbGpPWpGaD
Terlipressin—AVPR2—GPCR ligand binding—CALCB—thyroid cancer	0.00916	0.0174	CbGpPWpGaD
Terlipressin—Angiopathy—Vandetanib—thyroid cancer	0.00909	0.0192	CcSEcCtD
Terlipressin—AVPR2—G alpha (s) signalling events—CALCA—thyroid cancer	0.00875	0.0166	CbGpPWpGaD
Terlipressin—Malnutrition—Vandetanib—thyroid cancer	0.00872	0.0184	CcSEcCtD
Terlipressin—AVPR1B—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00809	0.0154	CbGpPWpGaD
Terlipressin—Hypertension—Vandetanib—thyroid cancer	0.00753	0.0159	CcSEcCtD
Terlipressin—AVPR1B—GPCR downstream signaling—CALCB—thyroid cancer	0.00752	0.0143	CbGpPWpGaD
Terlipressin—Chest pain—Vandetanib—thyroid cancer	0.00742	0.0156	CcSEcCtD
Terlipressin—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00742	0.0156	CcSEcCtD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00741	0.0141	CbGpPWpGaD
Terlipressin—Myocardial infarction—Sorafenib—thyroid cancer	0.00738	0.0156	CcSEcCtD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00737	0.0155	CcSEcCtD
Terlipressin—Nervous system disorder—Vandetanib—thyroid cancer	0.00698	0.0147	CcSEcCtD
Terlipressin—Skin disorder—Vandetanib—thyroid cancer	0.00691	0.0146	CcSEcCtD
Terlipressin—AVPR1B—Signaling by GPCR—CALCB—thyroid cancer	0.00683	0.013	CbGpPWpGaD
Terlipressin—AVPR1A—Peptide ligand-binding receptors—SST—thyroid cancer	0.0065	0.0124	CbGpPWpGaD
Terlipressin—AVPR2—Peptide ligand-binding receptors—SST—thyroid cancer	0.00646	0.0123	CbGpPWpGaD
Terlipressin—Dyspnoea—Vandetanib—thyroid cancer	0.00634	0.0134	CcSEcCtD
Terlipressin—AVPR1B—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00629	0.012	CbGpPWpGaD
Terlipressin—Cardiac disorder—Sorafenib—thyroid cancer	0.00627	0.0132	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—TSHR—thyroid cancer	0.00616	0.0117	CbGpPWpGaD
Terlipressin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00614	0.0129	CcSEcCtD
Terlipressin—Angiopathy—Sorafenib—thyroid cancer	0.00613	0.0129	CcSEcCtD
Terlipressin—Malnutrition—Sorafenib—thyroid cancer	0.00588	0.0124	CcSEcCtD
Terlipressin—Abdominal pain—Vandetanib—thyroid cancer	0.00562	0.0119	CcSEcCtD
Terlipressin—AVPR1A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00561	0.0107	CbGpPWpGaD
Terlipressin—AVPR2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00557	0.0106	CbGpPWpGaD
Terlipressin—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.0055	0.0116	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—PTCH1—thyroid cancer	0.00524	0.00997	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—CALCB—thyroid cancer	0.00521	0.00992	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—CALCB—thyroid cancer	0.00518	0.00985	CbGpPWpGaD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00513	0.00977	CbGpPWpGaD
Terlipressin—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00509	0.0107	CcSEcCtD
Terlipressin—Hypertension—Sorafenib—thyroid cancer	0.00508	0.0107	CcSEcCtD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00497	0.0105	CcSEcCtD
Terlipressin—Diarrhoea—Vandetanib—thyroid cancer	0.00487	0.0103	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—SST—thyroid cancer	0.00479	0.00912	CbGpPWpGaD
Terlipressin—Skin exfoliation—Epirubicin—thyroid cancer	0.00475	0.01	CcSEcCtD
Terlipressin—AVPR1A—Signaling by GPCR—CALCB—thyroid cancer	0.00474	0.00901	CbGpPWpGaD
Terlipressin—Nervous system disorder—Sorafenib—thyroid cancer	0.00471	0.00992	CcSEcCtD
Terlipressin—AVPR2—Signaling by GPCR—CALCB—thyroid cancer	0.0047	0.00894	CbGpPWpGaD
Terlipressin—Skin disorder—Sorafenib—thyroid cancer	0.00466	0.00983	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—CALCA—thyroid cancer	0.00461	0.00878	CbGpPWpGaD
Terlipressin—Vomiting—Vandetanib—thyroid cancer	0.00452	0.00954	CcSEcCtD
Terlipressin—Headache—Vandetanib—thyroid cancer	0.00446	0.0094	CcSEcCtD
Terlipressin—Pulmonary oedema—Epirubicin—thyroid cancer	0.00442	0.00933	CcSEcCtD
Terlipressin—Skin exfoliation—Doxorubicin—thyroid cancer	0.00439	0.00926	CcSEcCtD
Terlipressin—AVPR1A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00436	0.0083	CbGpPWpGaD
Terlipressin—AVPR2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00433	0.00824	CbGpPWpGaD
Terlipressin—Dyspnoea—Sorafenib—thyroid cancer	0.00428	0.00902	CcSEcCtD
Terlipressin—AVPR1A—GPCR ligand binding—TSHR—thyroid cancer	0.00427	0.00813	CbGpPWpGaD
Terlipressin—AVPR2—GPCR ligand binding—TSHR—thyroid cancer	0.00424	0.00807	CbGpPWpGaD
Terlipressin—Nausea—Vandetanib—thyroid cancer	0.00423	0.00891	CcSEcCtD
Terlipressin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00414	0.00874	CcSEcCtD
Terlipressin—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00409	0.00863	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—CALCB—thyroid cancer	0.00404	0.00768	CbGpPWpGaD
Terlipressin—Hot flush—Epirubicin—thyroid cancer	0.00386	0.00813	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—TRIM33—thyroid cancer	0.00383	0.00728	CbGpPWpGaD
Terlipressin—Menopausal symptoms—Epirubicin—thyroid cancer	0.00382	0.00806	CcSEcCtD
Terlipressin—Abdominal pain—Sorafenib—thyroid cancer	0.00379	0.008	CcSEcCtD
Terlipressin—Cardiac failure—Epirubicin—thyroid cancer	0.0037	0.0078	CcSEcCtD
Terlipressin—AVPR1A—GPCR ligand binding—PTCH1—thyroid cancer	0.00363	0.00691	CbGpPWpGaD
Terlipressin—Hyponatraemia—Epirubicin—thyroid cancer	0.00362	0.00764	CcSEcCtD
Terlipressin—AVPR2—GPCR ligand binding—PTCH1—thyroid cancer	0.00361	0.00686	CbGpPWpGaD
Terlipressin—Hot flush—Doxorubicin—thyroid cancer	0.00357	0.00753	CcSEcCtD
Terlipressin—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00354	0.00746	CcSEcCtD
Terlipressin—AVPR1B—GPCR downstream signaling—TSHR—thyroid cancer	0.00348	0.00663	CbGpPWpGaD
Terlipressin—Cardiac failure—Doxorubicin—thyroid cancer	0.00342	0.00721	CcSEcCtD
Terlipressin—Hyponatraemia—Doxorubicin—thyroid cancer	0.00335	0.00707	CcSEcCtD
Terlipressin—AVPR1A—GPCR ligand binding—SST—thyroid cancer	0.00332	0.00632	CbGpPWpGaD
Terlipressin—AVPR2—GPCR ligand binding—SST—thyroid cancer	0.0033	0.00627	CbGpPWpGaD
Terlipressin—Diarrhoea—Sorafenib—thyroid cancer	0.00328	0.00692	CcSEcCtD
Terlipressin—AVPR2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00328	0.00625	CbGpPWpGaD
Terlipressin—AVPR2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00328	0.00625	CbGpPWpGaD
Terlipressin—AVPR2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00323	0.00614	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR ligand binding—CALCA—thyroid cancer	0.0032	0.00608	CbGpPWpGaD
Terlipressin—AVPR2—GPCR ligand binding—CALCA—thyroid cancer	0.00318	0.00604	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—TSHR—thyroid cancer	0.00316	0.00602	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00311	0.00592	CbGpPWpGaD
Terlipressin—Vomiting—Sorafenib—thyroid cancer	0.00305	0.00643	CcSEcCtD
Terlipressin—Headache—Sorafenib—thyroid cancer	0.00301	0.00634	CcSEcCtD
Terlipressin—Nausea—Sorafenib—thyroid cancer	0.00285	0.00601	CcSEcCtD
Terlipressin—AVPR1A—Signaling Pathways—CALCB—thyroid cancer	0.0028	0.00532	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—CALCB—thyroid cancer	0.00278	0.00528	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—SST—thyroid cancer	0.00271	0.00515	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—PTCH1—thyroid cancer	0.00269	0.00512	CbGpPWpGaD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00266	0.00505	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—TRIM33—thyroid cancer	0.00265	0.00504	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TRIM33—thyroid cancer	0.00263	0.00501	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—CALCA—thyroid cancer	0.00261	0.00496	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—TCF7L1—thyroid cancer	0.00255	0.00486	CbGpPWpGaD
Terlipressin—Bradycardia—Epirubicin—thyroid cancer	0.00254	0.00536	CcSEcCtD
Terlipressin—AVPR1B—Signaling by GPCR—SST—thyroid cancer	0.00246	0.00468	CbGpPWpGaD
Terlipressin—AVPR2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00246	0.00468	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—TSHR—thyroid cancer	0.00241	0.00459	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—TSHR—thyroid cancer	0.0024	0.00456	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—CALCA—thyroid cancer	0.00237	0.0045	CbGpPWpGaD
Terlipressin—Bradycardia—Doxorubicin—thyroid cancer	0.00235	0.00496	CcSEcCtD
Terlipressin—Cardiac disorder—Epirubicin—thyroid cancer	0.00232	0.00488	CcSEcCtD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00229	0.00435	CbGpPWpGaD
Terlipressin—Angiopathy—Epirubicin—thyroid cancer	0.00226	0.00478	CcSEcCtD
Terlipressin—AVPR1A—Signaling by GPCR—TSHR—thyroid cancer	0.00219	0.00417	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—TSHR—thyroid cancer	0.00218	0.00414	CbGpPWpGaD
Terlipressin—Malnutrition—Epirubicin—thyroid cancer	0.00217	0.00458	CcSEcCtD
Terlipressin—AVPR1A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00216	0.0041	CbGpPWpGaD
Terlipressin—Cardiac disorder—Doxorubicin—thyroid cancer	0.00214	0.00452	CcSEcCtD
Terlipressin—AVPR1B—Signaling by GPCR—CDK1—thyroid cancer	0.00214	0.00408	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00214	0.00407	CbGpPWpGaD
Terlipressin—Angiopathy—Doxorubicin—thyroid cancer	0.0021	0.00442	CcSEcCtD
Terlipressin—AVPR2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00206	0.00393	CbGpPWpGaD
Terlipressin—Malnutrition—Doxorubicin—thyroid cancer	0.00201	0.00424	CcSEcCtD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00194	0.0037	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—SST—thyroid cancer	0.00188	0.00357	CbGpPWpGaD
Terlipressin—Hypertension—Epirubicin—thyroid cancer	0.00188	0.00396	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—TSHR—thyroid cancer	0.00187	0.00355	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—PTCH1—thyroid cancer	0.00186	0.00355	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—SST—thyroid cancer	0.00186	0.00355	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—PTCH1—thyroid cancer	0.00185	0.00352	CbGpPWpGaD
Terlipressin—Chest pain—Epirubicin—thyroid cancer	0.00185	0.0039	CcSEcCtD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00184	0.0035	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—PRKAR1A—thyroid cancer	0.00184	0.0035	CbGpPWpGaD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00184	0.00387	CcSEcCtD
Terlipressin—AVPR1A—GPCR downstream signaling—CALCA—thyroid cancer	0.00181	0.00344	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—CALCA—thyroid cancer	0.00179	0.00341	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—TCF7L1—thyroid cancer	0.00177	0.00337	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TCF7L1—thyroid cancer	0.00176	0.00334	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—MEN1—thyroid cancer	0.00176	0.00334	CbGpPWpGaD
Terlipressin—Nervous system disorder—Epirubicin—thyroid cancer	0.00174	0.00367	CcSEcCtD
Terlipressin—Hypertension—Doxorubicin—thyroid cancer	0.00174	0.00366	CcSEcCtD
Terlipressin—Tachycardia—Epirubicin—thyroid cancer	0.00173	0.00365	CcSEcCtD
Terlipressin—Skin disorder—Epirubicin—thyroid cancer	0.00172	0.00363	CcSEcCtD
Terlipressin—Chest pain—Doxorubicin—thyroid cancer	0.00171	0.00361	CcSEcCtD
Terlipressin—AVPR1A—Signaling by GPCR—SST—thyroid cancer	0.0017	0.00324	CbGpPWpGaD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0017	0.00358	CcSEcCtD
Terlipressin—AVPR2—Signaling by GPCR—SST—thyroid cancer	0.00169	0.00322	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—CALCA—thyroid cancer	0.00164	0.00312	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—CALCA—thyroid cancer	0.00163	0.0031	CbGpPWpGaD
Terlipressin—Nervous system disorder—Doxorubicin—thyroid cancer	0.00161	0.00339	CcSEcCtD
Terlipressin—Tachycardia—Doxorubicin—thyroid cancer	0.0016	0.00338	CcSEcCtD
Terlipressin—Skin disorder—Doxorubicin—thyroid cancer	0.00159	0.00336	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—PTCH1—thyroid cancer	0.00159	0.00302	CbGpPWpGaD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00158	0.00302	CbGpPWpGaD
Terlipressin—Dyspnoea—Epirubicin—thyroid cancer	0.00158	0.00333	CcSEcCtD
Terlipressin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00153	0.00323	CcSEcCtD
Terlipressin—AVPR1A—Signaling by GPCR—CDK1—thyroid cancer	0.00149	0.00283	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—CDK1—thyroid cancer	0.00147	0.00281	CbGpPWpGaD
Terlipressin—Dyspnoea—Doxorubicin—thyroid cancer	0.00146	0.00308	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—SST—thyroid cancer	0.00145	0.00276	CbGpPWpGaD
Terlipressin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00142	0.00299	CcSEcCtD
Terlipressin—Abdominal pain—Epirubicin—thyroid cancer	0.0014	0.00296	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—CALCA—thyroid cancer	0.0014	0.00266	CbGpPWpGaD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00135	0.00256	CbGpPWpGaD
Terlipressin—Abdominal pain—Doxorubicin—thyroid cancer	0.0013	0.00274	CcSEcCtD
Terlipressin—AVPR1A—Signaling Pathways—TSHR—thyroid cancer	0.0013	0.00246	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TSHR—thyroid cancer	0.00129	0.00245	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.00127	0.00242	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—CDK1—thyroid cancer	0.00127	0.00241	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—PRKAR1A—thyroid cancer	0.00126	0.00241	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—MEN1—thyroid cancer	0.00122	0.00232	CbGpPWpGaD
Terlipressin—Diarrhoea—Epirubicin—thyroid cancer	0.00121	0.00256	CcSEcCtD
Terlipressin—AVPR2—Signaling Pathways—MEN1—thyroid cancer	0.00121	0.0023	CbGpPWpGaD
Terlipressin—Vomiting—Epirubicin—thyroid cancer	0.00113	0.00238	CcSEcCtD
Terlipressin—Diarrhoea—Doxorubicin—thyroid cancer	0.00112	0.00237	CcSEcCtD
Terlipressin—Headache—Epirubicin—thyroid cancer	0.00111	0.00234	CcSEcCtD
Terlipressin—AVPR1A—Signaling Pathways—PTCH1—thyroid cancer	0.0011	0.00209	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—PTCH1—thyroid cancer	0.00109	0.00208	CbGpPWpGaD
Terlipressin—Nausea—Epirubicin—thyroid cancer	0.00105	0.00222	CcSEcCtD
Terlipressin—Vomiting—Doxorubicin—thyroid cancer	0.00104	0.0022	CcSEcCtD
Terlipressin—Headache—Doxorubicin—thyroid cancer	0.00103	0.00217	CcSEcCtD
Terlipressin—AVPR1B—Signaling Pathways—NRG1—thyroid cancer	0.00102	0.00193	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—SST—thyroid cancer	0.00101	0.00192	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—SST—thyroid cancer	0.001	0.0019	CbGpPWpGaD
Terlipressin—Nausea—Doxorubicin—thyroid cancer	0.000975	0.00206	CcSEcCtD
Terlipressin—AVPR1A—Signaling Pathways—CALCA—thyroid cancer	0.00097	0.00184	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—CALCA—thyroid cancer	0.000963	0.00183	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—TERT—thyroid cancer	0.000912	0.00174	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—CDK1—thyroid cancer	0.000878	0.00167	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—HIF1A—thyroid cancer	0.000873	0.00166	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—CDK1—thyroid cancer	0.000871	0.00166	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—NRAS—thyroid cancer	0.000769	0.00146	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—BRAF—thyroid cancer	0.000723	0.00137	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—NRG1—thyroid cancer	0.000704	0.00134	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—NRG1—thyroid cancer	0.000699	0.00133	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—KRAS—thyroid cancer	0.000662	0.00126	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—TERT—thyroid cancer	0.000632	0.0012	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TERT—thyroid cancer	0.000628	0.00119	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—HIF1A—thyroid cancer	0.000605	0.00115	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—HIF1A—thyroid cancer	0.000601	0.00114	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—HRAS—thyroid cancer	0.000562	0.00107	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—AKT1—thyroid cancer	0.000547	0.00104	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—NRAS—thyroid cancer	0.000533	0.00101	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—NRAS—thyroid cancer	0.000529	0.00101	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—CCND1—thyroid cancer	0.000527	0.001	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—PTEN—thyroid cancer	0.000509	0.000968	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—BRAF—thyroid cancer	0.000501	0.000953	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—BRAF—thyroid cancer	0.000497	0.000946	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—AKT1—thyroid cancer	0.000497	0.000945	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—KRAS—thyroid cancer	0.000459	0.000872	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—KRAS—thyroid cancer	0.000455	0.000866	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—NRAS—thyroid cancer	0.000454	0.000864	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—KRAS—thyroid cancer	0.000391	0.000744	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—HRAS—thyroid cancer	0.00039	0.000742	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—HRAS—thyroid cancer	0.000387	0.000736	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—AKT1—thyroid cancer	0.000379	0.000721	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—AKT1—thyroid cancer	0.000376	0.000716	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—CCND1—thyroid cancer	0.000366	0.000695	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—CCND1—thyroid cancer	0.000363	0.00069	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—PTEN—thyroid cancer	0.000353	0.000671	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—PTEN—thyroid cancer	0.00035	0.000666	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—TP53—thyroid cancer	0.000347	0.000661	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—AKT1—thyroid cancer	0.000344	0.000655	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—AKT1—thyroid cancer	0.000342	0.00065	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—HRAS—thyroid cancer	0.000332	0.000632	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—NRAS—thyroid cancer	0.000315	0.000599	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—NRAS—thyroid cancer	0.000313	0.000595	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—AKT1—thyroid cancer	0.000293	0.000558	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—KRAS—thyroid cancer	0.000271	0.000515	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—KRAS—thyroid cancer	0.000269	0.000512	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—TP53—thyroid cancer	0.000241	0.000458	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TP53—thyroid cancer	0.000239	0.000455	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—HRAS—thyroid cancer	0.00023	0.000438	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—HRAS—thyroid cancer	0.000229	0.000435	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—AKT1—thyroid cancer	0.000203	0.000387	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—AKT1—thyroid cancer	0.000202	0.000384	CbGpPWpGaD
